← Browse by Condition
Medical Condition

fgfr2 gene mutation

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 2
NCT06728410 Phase 2
Recruiting

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Enrollment
38 pts
Location
United States
Sponsor
Mehmet Akce
View Trial →